In September 2026, Merck unexpectedly discontinued its crucial antibiotic Recarbrio from the United States market without providing an explanation. Approved in 2019, the three-drug injection treats severe infections like hospital-acquired pneumonia. The Food and Drug Administration designated Recarbrio as a last-resort treatment to mitigate superbug resistance, which limited its commercial viability and highlights broader concerns about pharmaceutical commitment to the antibiotic field.
Details of the discontinuation
- ▪Merck discontinued its antibiotic Recarbrio from the United States market in September 2026 without providing an explanation for the decision.
- ▪Merck did not disclose sales figures for its antibiotic Recarbrio in its regulatory filings prior to discontinuing the drug in September 2026.
Broader concerns over antibiotic development
- ▪The discontinuation of Recarbrio by Merck in September 2026 highlights ongoing concerns regarding the commitment of large pharmaceutical companies to the antibiotic field.
- ▪Merck's discontinuation of Recarbrio in September 2026 occurred despite public health concerns regarding superbug resistance and the need for crucial antibiotic treatments.
Debatable claims
- ▪The FDA bears primary responsibility for the commercial failure of Recarbrio
- ▪Large pharmaceutical companies are no longer suitable partners for antibiotic development
- ▪Designating new antibiotics as 'treatments of last resort' does more harm than good
- ▪Merck should continue supplying Recarbrio to the United States market
Story comments
Loading comments…